Filing Flows

Filing Flows › Companies › Regen BioPharma › Cash flow

Regen BioPharma cash flow, quarter by quarter

Latest: Q3 FY26 · from the cash-flow statements filed with the SEC

Free cash flow−$24K in Q3 FY26 · −$445K over twelve months

Operating cash flow−$24K
Free cash flow−$24K

Analysis

In Q3 FY26, Regen BioPharma generated −$24K of operating cash flow. That is $32K more than in Q3 FY25 (−$56K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$445K; the largest uses were operating cash flow ($445K); besides operations, cash came from other financing ($444K); the cash balance fell by $2K.

Operating cash flow was −$24K against net income of −$638K. The largest differences: other non-cash +$662K, receivables −$27K, accrued liabilities −$8K.

Free cash flow

Regen BioPharma: free cash flow by quarterRegen BioPharma: free cash flow by quarter−$173KQ3 FY24−$207KQ4 FY24−$66KQ1 FY25−$101KQ2 FY25−$56KQ3 FY25−$198KQ1 FY26−$63KQ2 FY26−$24KQ3 FY26
Operating cash flow less capital spending.
Regen BioPharma: operating cash flow against capital spendingRegen BioPharma: operating cash flow against capital spendingOperating cash flowCapital spending−$173K$0Q3 FY24−$207K$0Q4 FY24−$66K$0Q1 FY25−$101K$0Q2 FY25−$56K$0Q3 FY25−$198K$0Q1 FY26−$63K$0Q2 FY26−$24K$0Q3 FY26
Latest (Q3 FY26): Operating cash flow −$24K, Capital spending $0.

Capital allocation, year by year

Regen BioPharma: where the cash came from (up) and went (down), by fiscal yearRegen BioPharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedFY21: Operating cash flow −$1.1MFY21FY22: Operating cash flow −$607KFY22: Net borrowing $499$499FY22FY23: Operating cash flow −$174KFY23: Net borrowing $244K$244KFY23FY24: Operating cash flow −$752KFY24: Net borrowing $67KFY24: Shares issued $564K$631KFY24FY25: Operating cash flow −$384KFY25: Net borrowing $200KFY25: Shares issued $58K$258KFY25
Over these 5 years operating cash flow totalled −$3.0M; the largest uses were operating cash flow ($3.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$70K
Debtnone
Net cash$70K
Cash runway2 months

Regen BioPharma is burning cash: its operations consume cash, a free cash flow of −$445K a year at the current rate against $70K of cash and investments: a runway of about 2 months before any new financing.

Where the cash came from and went

Regen BioPharma: sources (+) and uses (−) of cash, Q3 FY26Regen BioPharma: sources (+) and uses (−) of cash, Q3 FY26Operating cash flow−$24KOther financing$24KCash drawn (+) / kept (−)$32
Regen BioPharma: sources (+) and uses (−) of cash, TTM to Q3 FY26Regen BioPharma: sources (+) and uses (−) of cash, TTM to Q3 FY26Operating cash flow−$445KOther financing$444KCash drawn (+) / kept (−)$2K

From profit to cash

Regen BioPharma: net income to operating cash flow, Q3 FY26Regen BioPharma: net income to operating cash flow, Q3 FY26Net income−$638KOther non-cash$662KReceivables−$27KPayables$468Accrued liabilities−$8KOperating cash flow−$24K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 FY26−$24K—$32−$24K
Q2 FY26−$63K$50K$4K−$63K
Q1 FY26−$198K$192K$65K−$198K
Q3 FY25−$56K—$1−$56K
Q2 FY25−$101K—−$2K−$101K
Q1 FY25−$66K—$1K−$66K
Q4 FY24−$207K$28K$61K−$207K
Q3 FY24−$173K$135K$16K−$173K

Regen BioPharma: income statement and cash flow

Regen BioPharma, Q3 FY26: revenue $59K (0% year over year), operating margin 41.5%. The chart follows the revenue to costs, profit and cash.

Regen BioPharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.